恩他卡朋结构式
|
常用名 | 恩他卡朋 | 英文名 | Entacapone |
|---|---|---|---|---|
| CAS号 | 130929-57-6 | 分子量 | 305.286 | |
| 密度 | 1.4±0.1 g/cm3 | 沸点 | 526.6±50.0 °C at 760 mmHg | |
| 分子式 | C14H15N3O5 | 熔点 | 162-1630C | |
| MSDS | 美版 | 闪点 | 272.3±30.1 °C |
恩他卡朋用途Entacapone是特异的外周活性的邻苯二酚-O-甲基转移酶(COMT)抑制剂,IC50为151 nM。 |
| 中文名 | 恩他卡朋 |
|---|---|
| 英文名 | entacapone |
| 中文别名 | (2E)-2-氰基-3-(3,4-二羟基-5-硝基苯基)-N,N-二乙基-2-丙烯酰胺 | (E)-2-氰基-3-(3,4二羟基-5-硝基苯)-N,N二乙基丙烯酰胺 | 安托卡朋 F·S | 安托卡朋 | (E)-2-氰基-3-(3,4-二羟基-5-硝基苯基)-N,N-二乙基-2-丙烯酰胺 |
| 英文别名 | 更多 |
| 描述 | Entacapone是特异的外周活性的邻苯二酚-O-甲基转移酶(COMT)抑制剂,IC50为151 nM。 |
|---|---|
| 相关类别 | |
| 参考文献 |
| 密度 | 1.4±0.1 g/cm3 |
|---|---|
| 沸点 | 526.6±50.0 °C at 760 mmHg |
| 熔点 | 162-1630C |
| 分子式 | C14H15N3O5 |
| 分子量 | 305.286 |
| 闪点 | 272.3±30.1 °C |
| 精确质量 | 305.101166 |
| PSA | 130.38000 |
| LogP | 2.38 |
| 外观性状 | 黄色粉末 |
| 蒸汽压 | 0.0±1.4 mmHg at 25°C |
| 折射率 | 1.642 |
| 储存条件 | -20°C Freezer |
| 分子结构 | 1、 摩尔折射率:79.12 2、 摩尔体积(cm3/mol):219.2 3、 等张比容(90.2K):629.8 4、 表面张力(dyne/cm):68.1 5、 极化率(10-24cm3):31.36 |
| 计算化学 | 1.疏水参数计算参考值(XlogP):2.1 2.氢键供体数量:2 3.氢键受体数量:6 4.可旋转化学键数量:4 5.互变异构体数量:16 6.拓扑分子极性表面积130 7.重原子数量:22 8.表面电荷:0 9.复杂度:500 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:1 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
| 更多 | 1.性状:结晶。 2.熔点:162~163℃。 |
| 危害码 (欧洲) | Xn,T,F |
|---|---|
| 风险声明 (欧洲) | R10:Flammable. R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . R37/38:Irritating to respiratory system and skin . R41:Risk of serious damage to eyes. R62:Possible risk of impaired fertility. R38:Irritating to the skin. R36/37/38:Ir |
| 安全声明 (欧洲) | S26-S36-S39-S45-S36/37/39-S16 |
| 危险品运输编码 | UN 1986 3/PG 3 |
| WGK德国 | 1 |
| RTECS号 | KM5250000 |
| 包装等级 | III |
| 危险类别 | 3 |
| 海关编码 | 2942000000 |
1.83g 3,4-二羟基-5-硝基苯甲醛和1.5g N,N-二乙基氰基乙酰胺和催化量的哌啶乙酸盐溶于40ml干燥乙醇中,搅拌过夜,得2.23g粗品,收率73%,熔点153~156℃.
2. 在90℃下加热,将3.0kg粗品溶于含80gHBr(或40gHCl)的8.0kg乙酸(或甲酸)中.缓慢冷却到20℃,并在此温度搅拌20h,然后在15℃搅拌6h.过滤收集析出的结晶,先小心地用冷的(4℃)1L甲苯-乙酸(1:lv/v)的混合液洗,再用1L的冷甲苯洗.在真空和45℃下干燥,得2.4kg结晶性的纯的恩他卡朋,收率80%,mp162~163℃.
| 海关编码 | 2942000000 |
|---|
|
Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity.
Drug Metab. Dispos. 43(1) , 107-18, (2014) Understanding drug glucuronidation in the dog, a preclinical animal, is important but currently poorly characterized at the level of individual enzymes. We have constructed cDNAs for the 10 dog UDP-gl... |
|
|
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Parkinsonism Relat. Disord. 20(12) , 1335-40, (2014) IPX066, an investigational extended-release carbidopa-levodopa (CD-LD) preparation, has demonstrated a rapid attainment and prolonged maintenance of therapeutic LD plasma concentrations in advanced Pa... |
|
|
Entacapone and prostate cancer risk in patients with Parkinson's disease.
Mov. Disord 30(5) , 724-8, (2015) The association between Parkinson's disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE-PD study, prostate cancer developed in 9 patients (3.7%) receiving levodo... |
| (E)-2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide |
| (2E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylacrylamide |
| Comtan |
| Comtes |
| (2Z)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylacrylamide |
| OR-611 |
| 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide |
| MFCD00866580 |
| 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)- |
| (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide |
| Comtess |
| (E)-a-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide |
| Entacapone |
| 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2Z)- |